C

Clinical Best Solutions | Warsaw, Poland

Research site

(Unclaimed)

Location

Idzikowskiego 16, Warsaw, Mazovia, Poland

Site insights

Top conditions

Top treatments

ESK-001

Orismilast

Masitinib

LY4100511

LY4268989

Dice 853

Parent organization

This site is a part of Clinical Best Solutions

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis (ONWARD3)

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Active, not recruiting

Psoriasis

Severe Psoriasis

Drug: Open-Label Envudeucitinib

Drug: Blinded Envudeucitinib

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderatel...

Enrolling

Ulcerative Colitis (UC)

Ulcerative Colitis, Active Severe

Drug: Placebo

Drug: LY4268989

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive m...

Active, not recruiting

Progressive Multiple Sclerosis

Drug: Placebo

Drug: Masitinib (4.5)

Trial sponsors

A

D

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms